Prevalence of the C536T Mutation in the Tissue Factor Pathway Inhibitor (TFPI) Gene among Patients with Venous Thromboembolic Disease

Elena Rossi(Agostino Gemelli University Polyclinic), Katia Paciaroni(Università Cattolica del Sacro Cuore), Valerio De Stefano(Agostino Gemelli University Polyclinic), Mario Bazzan(Ospedale San Giovanni Bosco), Helen Ireland(Charing Cross Hospital)

Thrombosis and Haemostasis

January 1, 2001

10.1055/s-0037-1615774

Cited by 10

Related Papers

Three Months versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous Thrombosis

|New England Journal of Medicine|2001|599

Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis)

|Blood|2012|596

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

|Blood|2012|310

Enoxaparin for the Prevention of Venous Thromboembolism Associated With Central Vein Catheter: A Double-Blind, Placebo-Controlled, Randomized Study in Cancer Patients

|Journal of Clinical Oncology|2005|305

Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia

|Blood Cancer Journal|2015|273